

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number
WO 2004/016261 A1

(51) International Patent Classification⁷: **A61K 31/198**,
A61P 33/00

(81) Designated State (*national*): US.

(21) International Application Number:
PCT/JP2002/008209

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, SK, TR).

(22) International Filing Date: 12 August 2002 (12.08.2002)

Declarations under Rule 4.17:

(25) Filing Language: English

— *as to the identity of the inventor (Rule 4.17(i)) for all des-*
ignations

(26) Publication Language: English

— *as to applicant's entitlement to apply for and be granted a*
patent (Rule 4.17(ii)) for all designations

(71) Applicants and

— *as to applicant's entitlement to apply for and be granted a*
patent (Rule 4.17(ii)) for all designations

(72) Inventors: MURAYAMA, Yuuichi [JP/JP]; 6-13-205,
Matsushiro 3-chome, Tsukuba-shi, Ibaraki 305-0035
(JP). MORIYAMA, Masami [JP/JP]; 13-20-311, Bessho
1-chome, Minami-ku, Yokohama-shi, Kanagawa 232-0064
(JP).

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*
— *with amended claims and statement*

(74) Agent: KUSAMA, Osamu; KUSAMA PATENT
OFFICE, 7F, Iwata Bldg., 5-12, Iidabashi 4-chome, Chiy-
oda-ku, Tokyo 102-0072 (JP).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR SUPPRESSING PROLIFERATION OF ABNORMAL PRION PROTEIN WITH LEUCINE,
ISOLEUCINE OR VALINE

(57) Abstract: A method for suppressing proliferation of abnormal prion proteins is provided. Specifically, the method involves systemically, orally, intracerebrally or intraspinally administering an essential amino acid, in particular, one having a branched side chain, that is, one selected from leucine, isoleucine, and valine. Of these, leucine is most preferred.



WO 2004/016261 A1